New Immunotherapy Drugs Before Surgery for Advanced Colorectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to treat advanced colorectal cancer that can be removed. The goal is to help the immune system fight cancer cells and improve outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer (adenocarcinoma) confirmed by biopsy that is advanced but can be surgically removed
- Your tumor is microsatellite stable (MSS) or mismatch repair proficient (pMMR)—a genetic test result your doctor can check
- You have not received any prior cancer treatment (chemotherapy, radiation, immunotherapy, or surgery for cancer)
- You are at least 18 years old and healthy enough to tolerate treatment (ECOG performance status ≤ 2)
- Your blood counts and liver/kidney function are adequate for the study drugs
- If you can have children, you agree to use effective birth control during and for several months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) given before surgery for early-stage rectal cancer that is MSS/pMMR. The goal is to see if this treatment can shrink the tumor and improve outcomes compared to standard care.
This trial tests two new immunotherapy drugs (botensilimab and balstilimab) given after standard treatment for stage II or III colorectal cancer. The drugs are designed to boost your immune system to prevent cancer from coming back, especially if cancer cells are detected in your blood.
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
This trial tests a combination of chemotherapy (FOLFOX) and two immunotherapies (botensilimab and balstilimab) before surgery for patients with localized rectal cancer. It aims to see if adding immunotherapy helps shrink the tumor and improve outcomes.
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
This trial tests two immunotherapy drugs (ADG126 and pembrolizumab) given before surgery for locally advanced colorectal cancer that hasn't spread. It aims to shrink tumors and improve outcomes.
Hear when a new Stage IIB Rectal Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.